Transit Scientific receives FDA clearance for angioplasty platform

2022-10-28
The XO RX 2.2F and XO RX 3.8F Platform received the clearance to crack, break, and dilate stenoses in peripheral arteries and arteriovenous dialysis fistula-associated lesions Transit Scientific’s XO RX 3.8F angioplasty balloons. (Credit: PR Newswire/ Transit Scientific) Medical devices developer Transit Scientific has received US Food and Drug Administration (FDA) clearance for its XO RX 2.2F and XO RX 3.8F Platform to crack, break, and dilate stenoses in peripheral arteries and arteriovenous dialysis fistula-associated lesions. XO Platforms are said to be simple to use, minimally invasive, use existing angioplasty balloons and guidewires and preserve patient treatment options. The XO RX and XO OTW (over-the-wire) exoskeleton devices, which slip onto a variety of commercially available angioplasty balloons, include up to (22) rotating struts. The struts rotate 90 degrees during balloon inflation to crack, break and enlarge calcified stenotic atherosclerotic lesions and intimal hyperplastic lesions, Transit Scientific claimed. They can also be used to prepare vessels for other types of treatment. Transit Scientific chief operating officer Jennifer Arnold said: “The XO RX platform sets new standards for low-profile, flexibility, and performance. “Patients and clinicians need more tools to crack, break, and dilate occlusive lesions in patients with cardiovascular disease. “XO RX allows clinicians to add XO technology to 100s of angioplasty balloons covering a wide range of diameters and lengths with just a few SKUs.” By counter-rotating 90 degrees upon deflation, the XO RX and XO OTW devices are intended to reduce shear and facilitate balloon rewrap. The medical device maker said that medical professionals can send fluids from the hub to the balloon before, during, or after inflation using XO OTW. There is no need for consoles, expensive capital equipment, or a challenging learning curve. The XO RX Percutaneous Transluminal Angioplasty System is designed to be used with a PTA balloon to treat obstructive lesions of natural or artificial arteriovenous dialysis fistulas. It also facilitates dilation and apposition of the scoring surface to the stenotic material in the iliac, femoral, ilio-femoral, popliteal, and renal arteries. The 2.2F and 3.8F versions of XO RX can accommodate standard PTA balloons with an outer diameter of 1.5 to 7mm and a length of 20 to 200mm, minimising the need for inventory.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路,让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。